Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 6/2013

01.08.2013 | Original Article

Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway

verfasst von: Thomas Arnesen, Nina Glomnes, Siri Strømsøy, Stian Knappskog, Anette Heie, Lars A. Akslen, Marianne Grytaas, Jan Erik Varhaug, Oliver Gimm, Michael Brauckhoff

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary aldosteronism (PA) is a frequent cause (about 10 %) of hypertension. Some cases of PA were recently found to be caused by mutations in the potassium channel KCNJ5. Our objective was to determine the mutation status of KCNJ5 and seven additional candidate genes for tumorigenesis: YY1, FZD4, ARHGAP9, ZFP37, KDM5C, LRP1B, and PDE9A and, furthermore, the surgical outcome of PA patients who underwent surgery in Western Norway.

Methods

Twenty-eight consecutive patients with aldosterone-producing adrenal tumors (20 patients with single adenoma, 8 patients with unilateral multiple adenomas or hyperplasia) who underwent surgery were included in this study. All patients were operated on by uncomplicated laparoscopic total adrenalectomy. Genomic DNA was isolated from tumor and non-tumor adrenocortical tissue, and DNA sequencing revealed the mutation status.

Results

Ten out of 28 (36 %) patients with PA displayed tumor mutations in KCNJ5 (p. G151R and L168R) while none were found in the corresponding non-tumor samples. No mutations were found in the other seven candidate genes screened. The presence of KCNJ5 mutations was associated with lower blood pressure and a higher chance for cure by surgery when compared to patients harboring the KCNJ5 wild type.

Conclusions

KCNJ5 mutations are associated with a better surgical outcome. Preoperative identification of the mutation status might have impact on surgical strategy (total vs. subtotal adrenalectomy).
Literatur
1.
Zurück zum Zitat Young WF (2007) Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66(5):607–618CrossRef Young WF (2007) Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66(5):607–618CrossRef
2.
Zurück zum Zitat Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243–1248PubMedCrossRef Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243–1248PubMedCrossRef
3.
Zurück zum Zitat Conn JW (1955) Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45(1):3–17PubMed Conn JW (1955) Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45(1):3–17PubMed
4.
Zurück zum Zitat Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85(8):2854–2859PubMedCrossRef Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85(8):2854–2859PubMedCrossRef
5.
Zurück zum Zitat Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89(3):1045–1050PubMedCrossRef Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89(3):1045–1050PubMedCrossRef
6.
Zurück zum Zitat Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293–2300PubMedCrossRef Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293–2300PubMedCrossRef
7.
Zurück zum Zitat Stowasser M (2009) Update in primary aldosteronism. J Clin Endocrinol Metab 94(10):3623–3630PubMedCrossRef Stowasser M (2009) Update in primary aldosteronism. J Clin Endocrinol Metab 94(10):3623–3630PubMedCrossRef
8.
Zurück zum Zitat Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C et al (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331(6018):768–772PubMedCrossRef Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C et al (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331(6018):768–772PubMedCrossRef
9.
Zurück zum Zitat Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, Clapham DE (1995) The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins. Nature 374(6518):135–141PubMedCrossRef Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, Clapham DE (1995) The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins. Nature 374(6518):135–141PubMedCrossRef
10.
Zurück zum Zitat Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP (2008) A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 93(8):3117–3123PubMedCrossRef Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP (2008) A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 93(8):3117–3123PubMedCrossRef
11.
Zurück zum Zitat Mulatero P (2008) A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. J Clin Endocrinol Metab 93(8):2972–2974PubMedCrossRef Mulatero P (2008) A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. J Clin Endocrinol Metab 93(8):2972–2974PubMedCrossRef
12.
Zurück zum Zitat Akerstrom T, Crona J, Delgado VA, Starker LF, Cupisti K, Willenberg HS et al (2012) Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 7(7):e41926PubMedCrossRef Akerstrom T, Crona J, Delgado VA, Starker LF, Cupisti K, Willenberg HS et al (2012) Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 7(7):e41926PubMedCrossRef
13.
Zurück zum Zitat Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S et al (2012) Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 59(3):587–591PubMedCrossRef Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S et al (2012) Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 59(3):587–591PubMedCrossRef
14.
Zurück zum Zitat Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L et al (2012) Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 59(3):592–598PubMedCrossRef Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L et al (2012) Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 59(3):592–598PubMedCrossRef
15.
Zurück zum Zitat Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV et al (2012) Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 97(8):E1567–E1572PubMedCrossRef Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV et al (2012) Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 97(8):E1567–E1572PubMedCrossRef
16.
Zurück zum Zitat Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F et al (2012) KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 59(2):235–240PubMedCrossRef Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F et al (2012) KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 59(2):235–240PubMedCrossRef
17.
Zurück zum Zitat Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N et al (2012) Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 97(4):1311–1319PubMedCrossRef Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N et al (2012) Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 97(4):1311–1319PubMedCrossRef
18.
Zurück zum Zitat Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al (2012) Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 14(2):R47PubMedCrossRef Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al (2012) Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 14(2):R47PubMedCrossRef
19.
Zurück zum Zitat Fu B, Zhang X, Wang GX, Lang B, Ma X, Li HZ et al (2011) Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 185(5):1578–1582PubMedCrossRef Fu B, Zhang X, Wang GX, Lang B, Ma X, Li HZ et al (2011) Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 185(5):1578–1582PubMedCrossRef
20.
Zurück zum Zitat Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA et al (2008) Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg 32(5):847–853PubMedCrossRef Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA et al (2008) Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg 32(5):847–853PubMedCrossRef
21.
Zurück zum Zitat Fendrich V, Ramaswamy A, Nies C (2003) Hyperaldosteronism persisting after subtotal adrenalectomy. Chirurg 74(5):473–477, Article in GermanPubMedCrossRef Fendrich V, Ramaswamy A, Nies C (2003) Hyperaldosteronism persisting after subtotal adrenalectomy. Chirurg 74(5):473–477, Article in GermanPubMedCrossRef
22.
Zurück zum Zitat Eloubeidi MA, Black KR, Tamhane A, Eltoum IA, Bryant A, Cerfolio RJ (2010) A large single-center experience of EUS-guided FNA of the left and right adrenal glands: diagnostic utility and impact on patient management. Gastrointest Endosc 71(4):745–753PubMedCrossRef Eloubeidi MA, Black KR, Tamhane A, Eltoum IA, Bryant A, Cerfolio RJ (2010) A large single-center experience of EUS-guided FNA of the left and right adrenal glands: diagnostic utility and impact on patient management. Gastrointest Endosc 71(4):745–753PubMedCrossRef
Metadaten
Titel
Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway
verfasst von
Thomas Arnesen
Nina Glomnes
Siri Strømsøy
Stian Knappskog
Anette Heie
Lars A. Akslen
Marianne Grytaas
Jan Erik Varhaug
Oliver Gimm
Michael Brauckhoff
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 6/2013
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-013-1093-2

Weitere Artikel der Ausgabe 6/2013

Langenbeck's Archives of Surgery 6/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.